Sex differences in LDL ‐C reduction response to evolocumab: A propensity score matching analysis
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2024
DOI: 10.1002/phar.4619 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024. Verfasst von Ye-Qian He und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of …. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Propensity Score, Cholesterol, LDL, Anticholesteremic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
Background
Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have been shown to improve cardiovascular outcomes by reducing low‐density lipoprotein cholesterol (LDL‐C). However, sex differences in the efficacy of evolocumab remain unclear. This study aimed to investigate sex differences in the efficacy of evolocumab using real‐world data.
Method
Data were collected from the First Affiliated Hospital of Guangxi Medical University. A total of 416 eligible patients were selected from 1463 patients treated with evolocumab for secondary prevention. Clinical data, including individual characteristics and lipids profiles, were recorded. Propensity score matching (PSM) was used to control for potential confounders, with covariates including age, body mass index, smoking status, and diabetes. All eligible participants were propensity‐matched 1:1 for female versus male with a match tolerance of 0.02. The efficacy of evolocumab in females and males was compared by PSM‐adjusted analysis.
Results
In the PSM analysis, a significant difference was found in the relative percentage reduction of LDL‐C between females and males (−42.7% vs. −54.4%, p < 0.001). In addition, the absolute LDL‐C reduction was lower in females compared to males (interquartile range: −1.5 [−2.2, −0.8] mmol/L vs. −1.9 [−2.5, −1.0] mmol/L, p = 0.018). The rate of target LDL‐C attainment was lower in females than in males after treatment with evolocumab (21.6% vs. 39.8%, p = 0.009).
Conclusion
These results suggest that males have a better response to evolocumab in term of LDL‐C reduction compared to females.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.
ORCID-Profile: Tao-Tao Liu, Xia Jiang, Jie-Jiu Lu
Zitieren
APA
He, Y. Q., Wei, Y. Q., Huang, G. M., Liu, G. P., Lin, Z. Q., Liu, T. T., Jiang, X., & Lu, J. J. (2024). Sex differences in LDL ‐C reduction response to evolocumab: A propensity score matching analysis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.4619
Vancouver
He YQ, Wei YQ, Huang GM, Liu GP, Lin ZQ, Liu TT, et al. Sex differences in LDL ‐C reduction response to evolocumab: A propensity score matching analysis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2024. doi:10.1002/phar.4619
BibTeX
@article{He2024,
author = {He, Ye-Qian and Wei, Yu-Qing and Huang, Guang-Ming and Liu, Guo-Ping and Lin, Zhong-Qiu and Liu, Tao-Tao and Jiang, Xia and Lu, Jie-Jiu},
title = {Sex differences in LDL ‐C reduction response to evolocumab: A propensity score matching analysis},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2024},
doi = {10.1002/phar.4619}
}
EUVIMED